You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,273,296

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,273,296

Title:	Treatment for dupuytren\'s disease
Abstract:	Musculoskeletal fibroproliferative disorders, such as Dupuytren\'s disease may be treated by administering locally a TNF-.alpha. antagonist. TNF-.alpha. antagonists find particular utility in inhibiting the progression of early disease state Dupuytren\'s disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren\'s disease and, in particular inhibiting recurrence.
Inventor(s):	Nanchahal; Jagdeep (Richmond Surrey, GB), Midwood; Kim Suzanne (London, GB)
Assignee:	OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB)
Application Number:	14/852,442
Patent Claims:	1. A method for treating a patient with early disease state adhesive capsulitis comprising injecting an amount of a TNF-.alpha. antagonist effective to treat the patient directly into one or more clinical or histological nodules at the site of the early disease state adhesive capsulitis, so as to treat the patient. 2. A method of claim 1, wherein the TNF-.alpha. antagonist is selected from one or more of Infliximab, Adalimumab, Certolizumab pegol, Golimumab or Etanercept. 3. A method of claim 1, wherein the TNF-.alpha. antagonist is an anti-TNF-.alpha. antibody. 4. A method of claim 1, wherein the TNF-.alpha. antagonist is Infliximab. 5. A method of claim 1, wherein the TNF-.alpha. antagonist is Adalimumab. 6. A method of claim 1, wherein the TNF-.alpha. antagonist is Certolizumab pegol. 7. A method of claim 1, wherein the TNF-.alpha. antagonist is Golimumab. 8. A method of claim 1, wherein the TNF-.alpha. antagonist is Etanercept. 9. A method of claim 1 further comprising administering an extracellular matrix degradation, depletion or cleavage agent. 10. A method of claim 9, wherein the extracellular matrix degradation, depletion or cleavage agent is a matrix metalloproteinase and/or a collagenase. 11. A method of claim 9, wherein the extracellular matrix degradation, depletion or cleavage agent is administered locally to the disease site.

Details for Patent 10,273,296

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2030-10-30
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2030-10-30
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2030-10-30
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2030-10-30
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2030-10-30
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2030-10-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.